Top

Published in:

28-10-2023 | Asbestos-Related Disease | REVIEW

Asbestos-Related Diseases and Its Impact on Health: An Updated Review Article

Authors: Wasey Ali Yadullahi Mir, Ayusha Poudel, Anurag Adhikari, Dhan Bahadur Shrestha, Yubraj Sedhai, Peter LaCamera, Andrew Moraco

Published in: Current Pulmonology Reports | Issue 4/2023

Abstract

Purpose of Review

Asbestos is a naturally occurring mineral with a wide range of application in various industries. It has been linked with respiratory and non-respiratory illnesses. We aim to discuss the various pathologies caused due to asbestos exposure with succinct coverage of all areas of asbestosis study.

Recent Findings

Asbestos continues to be used in many industries. Currently, cosmetic products contaminated by asbestos raise the problem of continuous exposure to a proven carcinogen. Various conditions like effusions, plaques, pneumoconiosis, mesothelioma, and lung cancer are associated with it. The development of respiratory problems has a dose–response relationship with asbestos. Currently, no pharmacological therapy has demonstrated efficacy in the treatment of asbestosis.

Summary

The diagnosis of asbestos-related illnesses should have a clear history of exposure to the mineral and suggestive clinical and imaging findings. As the therapy of asbestos-related illnesses is not curative, the main aim should be to limit asbestos exposure. Besides, alternative materials should be promoted instead of asbestos to reduce its usage further.

Gulati M, Redlich CA. Asbestosis and environmental causes of usual interstitial pneumonia. Curr Opin Pulm Med. 2015;21(2):193–200. https://doi.org/10.1097/MCP.0000000000000144.CrossRefPubMedPubMedCentral

•• Types of asbestos - chrysotile, actinolite, tremolite & more. https://www.asbestos.com/asbestos/types/. Accessed 8 Dec 2022. Papers provide important information on types of fibers/statistics and a regulation of asbestos seen in USA.

• Asbestos Statistics and Information | U.S. Geological Survey. https://www.usgs.gov/centers/national-minerals-information-center/asbestos-statistics-and-information. Accessed 9 Dec 2022. Papers provide important information on types of fibers/statistics and a regulation of asbestos seen in USA.

• Kamp DW. Asbestos-induced lung diseases: an update. Transl Res. 2009;153(4):143. https://doi.org/10.1016/J.TRSL.2009.01.004. Covers the mechanisms/pathogenesis of asbestos affecting humans.CrossRefPubMedPubMedCentral

O’Reilly KMA, McLaughlin AM, Beckett WS, Sime PJ. Asbestos-related lung disease. Am Fam Physician. 2007;75(5):683–8. https://www.aafp.org/pubs/afp/issues/2007/0301/p683.html. Accessed 29 Apr 2023.

Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health. 2013;34:205–16. https://doi.org/10.1146/ANNUREV-PUBLHEALTH-031811-124704.CrossRefPubMed

Bird T, Steffen JE, Tran TH, Egilman DS. A review of the talc industry’s influence on federal regulation and scientific standards for asbestos in talc. New Solut. 2021;31(2):152. https://doi.org/10.1177/1048291121996645.CrossRefPubMedPubMedCentral

Gordon RE, Fitzgerald S, Millette J. Asbestos in commercial cosmetic talcum powder as a cause of mesothelioma in women. Int J Occup Environ Health. 2014;20(4):318. https://doi.org/10.1179/2049396714Y.0000000081.CrossRefPubMedPubMedCentral

Diandini R, Takahashi K, Park EK, et al. Potential years of life lost (PYLL) caused by asbestos-related diseases in the world. Am J Ind Med. 2013;56(9):993–1000. https://doi.org/10.1002/AJIM.22206.CrossRef

10.

Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global asbestos disaster. Int J Environ Res Public Health. 2018. https://doi.org/10.3390/IJERPH15051000.CrossRefPubMedPubMedCentral

11.

• Nicholson WJ, Perkel G, Selikoff IJ. Occupational exposure to asbestos: population at risk and projected mortality–1980-2030. Am J Ind Med. 1982;3(3):259–311. https://doi.org/10.1002/AJIM.4700030305. Provide trajectory of asthma in isa and related mortality.CrossRefPubMed

12.

LaDou J. The asbestos cancer epidemic. Environ Health Perspect. 2004;112(3):285. https://doi.org/10.1289/EHP.6704.CrossRefPubMedPubMedCentral

13.

Types of asbestos fibers | Classifying asbestos | Asbestos network. https://www.asbestosnetwork.com/what-is-asbestos/types-of-fibers/. Accessed 9 Dec 2022.

14.

Asbestos Statistics and Information | U.S. Geological Survey. https://www.usgs.gov/centers/national-minerals-information-center/asbestos-statistics-and-information. Accessed 29 Apr 2023.

15.

Document Display | NEPIS | US EPA. National Service Center for Environmental Publications (NSCEP).

16.

Lorber M, Gibb H, Grant L, Pinto J, Pleil J, Cleverly D. Assessment of inhalation exposures and potential health risks to the general population that resulted from the collapse of the World Trade Center towers. Risk Anal. 2007;27(5):1203–21. https://doi.org/10.1111/J.1539-6924.2007.00956.X.CrossRefPubMed

17.

• Asbestos toxicity: what are U.S. standards and regulations for asbestos levels? | Environmental Medicine | ATSDR. Papers provide important information on types of fibers/ statistics and a regulation of asbestos seen in USA.

18.

on the protection of workers from the risks related to exposure to asbestos at work (codified version) (Text with EEA relevance). Published online 2009.

19.

Lemen RA, Landrigan PJ. Toward an asbestos ban in the United States. Int J Environ Res Public Health. 2017. https://doi.org/10.3390/ijerph14111302.CrossRefPubMedPubMedCentral

20.

Baur X, Woitowitz HJ, Budnik LT, et al. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Critical need for revision of the 2014 update. Am J Ind Med. 2017;60(5):411–21. https://doi.org/10.1002/AJIM.22709.CrossRefPubMed

21.

SH P, DM K, BH K, YK K, JE K. Risk assessment of gastric cancer associated with asbestosis: a case report. Ann Occup Environ Med. 2015. https://doi.org/10.1186/S40557-015-0061-4.CrossRef

22.

Park S, Park J, Lee E, et al. Ovarian cancer in a former asbestos textile factory worker: a case report. Ann Occup Environ Med. 2018. https://doi.org/10.1186/S40557-018-0277-1.CrossRefPubMedPubMedCentral

23.

Harris EJA, Musk A, de Klerk N, Reid A, Franklin P, Brims FJH. Diagnosis of asbestos-related lung diseases. Expert Rev Respir Med. 2019;13(3):241–9. https://doi.org/10.1080/17476348.2019.1568875.CrossRefPubMed

24.

Lazarus AA, Philip A. Asbestosis. Dis Mon. 2011;57(1):14–26. https://doi.org/10.1016/J.DISAMONTH.2010.11.004.CrossRefPubMed

25.

Bayram M, Bakan ND. Environmental exposure to asbestos: from geology to mesothelioma. Curr Opin Pulm Med. 2014;20(3):301–7. https://doi.org/10.1097/MCP.0000000000000053.CrossRefPubMed

26.

Niklinski J, Niklinska W, Chyczewska E, et al. The epidemiology of asbestos-related diseases. Lung Cancer. 2004. https://doi.org/10.1016/J.LUNGCAN.2004.04.008.CrossRefPubMed

27.

Wagner GR. Asbestosis and silicosis. Lancet. 1997;349(9061):1311–5. https://doi.org/10.1016/S0140-6736(96)07336-9.CrossRefPubMed

28.

Nielsen LS, Bælum J, Rasmussen J, et al. Occupational asbestos exposure and lung cancer–a systematic review of the literature. Arch Environ Occup Health. 2014;69(4):191–206. https://doi.org/10.1080/19338244.2013.863752.CrossRefPubMed

29.

Magnani C, Terracini B, Ivaldi C, et al. A cohort study on mortality among wives of workers in the asbestos cement industry in Casale Monferrato, Italy. Br J Ind Med. 1993;50(9):779–84. https://doi.org/10.1136/OEM.50.9.779.CrossRefPubMedPubMedCentral

30.

Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C. Cancer mortality and incidence of mesothelioma in a cohort of wives of asbestos workers in Casale Monferrato, Italy. Environ Health Perspect. 2007;115(10):1401. https://doi.org/10.1289/EHP.10195.CrossRefPubMedPubMedCentral

31.

Lippmann M. Effects of fiber characteristics on lung deposition, retention, and disease. Environ Health Perspect. 1990;88:311. https://doi.org/10.1289/EHP.9088311.CrossRefPubMedPubMedCentral

32.

Brody AR, Hill LH, Adkins B, O’Connor RW. Chrysotile asbestos inhalation in rats: deposition pattern and reaction of alveolar epithelium and pulmonary macrophages. Am Rev Respir Dis. 1981;123(6):670–9. https://doi.org/10.1164/ARRD.1981.123.6.670.CrossRefPubMed

33.

Chang LY, Overby LH, Brody AR, Crapo JD. Progressive lung cell reactions and extracellular matrix production after a brief exposure to asbestos. Am J Pathol. 1988;131(1):156.PubMedPubMedCentral

34.

• Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax. 1999;54(7):638–52. https://doi.org/10.1136/THX.54.7.638. Covers the mechanisms/pathogenesis of asbestos affecting humans.CrossRefPubMedPubMedCentral

35.

Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1666–80. https://doi.org/10.1164/AJRCCM.157.5.9707141.CrossRefPubMed

36.

Mossman BT, Bignon J, Corn M, Seaton A, Gee JBL. Asbestos: scientific developments and implications for public policy. Science. 1990;247(4940):294–301. https://doi.org/10.1126/SCIENCE.2153315.CrossRefPubMed

37.

Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 1996;14(5):466–80. https://doi.org/10.3109/07357909609018904.CrossRefPubMed

38.

Rom WN, Travis WD, Brody AR. Cellular and molecular basis of the asbestos-related diseases. Am Rev Respir Dis. 1991;143(2):408–22. https://doi.org/10.1164/AJRCCM/143.2.408.CrossRefPubMed

39.

Kamp DW, Graceffa P, Pryor WA, Weitzman SA. The role of free radicals in asbestos-induced diseases. Free Radic Biol Med. 1992;12(4):293–315. https://doi.org/10.1016/0891-5849(92)90117-Y.CrossRefPubMed

40.

• Sayan M, Mossman BT. The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases. Part Fibre Toxicol. 2016. https://doi.org/10.1186/S12989-016-0162-4. Covers the mechanisms/pathogenesis of asbestos affecting humans.CrossRefPubMedPubMedCentral

41.

Hillegass JM, Miller JM, MacPherson MB, et al. Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol. 2013;10(1):39. https://doi.org/10.1186/1743-8977-10-39.CrossRefPubMedPubMedCentral

42.

Berman DW, Crump KS. A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol. 2008;38(Suppl 1):49–73. https://doi.org/10.1080/10408440802273156.CrossRefPubMed

43.

Neri M, Ugolini D, Dianzani I, et al. Genetic susceptibility to malignant pleural mesothelioma and other asbestos-associated diseases. Mutat Res Rev Mutat Res. 2008;659(1–2):126–36. https://doi.org/10.1016/J.MRREV.2008.02.002.CrossRef

44.

Neri M, Taioli E, Filiberti R, et al. Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations. Int J Hyg Environ Health. 2006;209(4):393–8. https://doi.org/10.1016/j.ijheh.2006.03.002.CrossRefPubMed

45.

Kukkonen MK, Hämäläinen S, Kaleva S, et al. Genetic susceptibility to asbestos-related fibrotic pleuropulmonary changes. Eur Respir J. 2011;38(3):672–8. https://doi.org/10.1183/09031936.00049810.CrossRefPubMed

46.

Zephaniah HS, Aremu SO. Asbestos: a silent potent killer. Eur J Environ Public Health. 2019;3(2):em0030. https://doi.org/10.29333/EJEPH/5906.

47.

Paris C, Thierry S, Brochard P, et al. Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data. Eur Respir J. 2009;34(1):72–9. https://doi.org/10.1183/09031936.00094008.CrossRefPubMed

48.

Mastrangelo G, Ballarin MN, Bellini E, et al. Asbestos exposure and benign asbestos diseases in 772 formerly exposed workers: dose-response relationships. Am J Ind Med. 2009;52(8):596–602. https://doi.org/10.1002/AJIM.20713.CrossRefPubMed

49.

Wolff H, Vehmas T, Oksa P, Rantanen J, Vainio H. Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scand J Work Environ Health. 2015;41(1):5–15. https://doi.org/10.5271/SJWEH.3462.CrossRefPubMed

50.

Lee YCG, Singh B, Pang SC, De Klerk NH, Hillman DR, Musk AW. Radiographic (ILO) readings predict arterial oxygen desaturation during exercise in subjects with asbestosis. Occup Environ Med. 2003;60(3):201–6. https://doi.org/10.1136/OEM.60.3.201.CrossRefPubMedPubMedCentral

51.

Roggli VL, Gibbs AR, Attanoos R, et al. Pathology of asbestosis- an update of the diagnostic criteria: report of the Asbestosis Committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462–80. https://doi.org/10.5858/134.3.462.CrossRefPubMed

52.

Weill H, Hughes JM, Churg AM. Changing trends in US mesothelioma incidence. Occup Environ Med. 2004;61(5):438–41. https://doi.org/10.1136/oem.2003.010165.CrossRefPubMedPubMedCentral

53.

Marsh GM, Riordan AS, Keeton KA, Benson SM. Non-occupational exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Occup Environ Med. 2017;74(11):838–46. https://doi.org/10.1136/OEMED-2017-104383.CrossRefPubMed

54.

Ramada Rodilla JM, Calvo Cerrada B, Serra Pujadas C, Delclos GL, Benavides FG. Fiber burden and asbestos-related diseases: an umbrella review. Gac Sanit. 2021. https://doi.org/10.1016/J.GACETA.2021.04.001.CrossRefPubMedPubMedCentral

55.

Markowitz S. Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues. Semin Respir Crit Care Med. 2015;36(3):334–46. https://doi.org/10.1055/S-0035-1549449.CrossRefPubMed

56.

Campanella NC, Silva EC, Dix G, et al. Mutational profiling of driver tumor suppressor and oncogenic genes in Brazilian malignant pleural mesotheliomas. Pathobiology. 2020;87(3):208–16. https://doi.org/10.1159/000507373.CrossRefPubMed

57.

Muruganandan S, Alfonso H, Franklin P, et al. Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma. Br J Cancer. 2017;116(6):703–8. https://doi.org/10.1038/bjc.2017.20.CrossRefPubMedPubMedCentral

58.

Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg. 2004;78(5):1774–6. https://doi.org/10.1016/j.athoracsur.2004.05.007.CrossRefPubMed

59.

Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620-626.e3. https://doi.org/10.1016/j.jtcvs.2007.10.054.CrossRefPubMed

60.

Gomez DR, Rimner A, Simone CB, et al. The use of radiation therapy for the treatment of malignant pleural mesothelioma: expert opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2019;14(7):1172–83. https://doi.org/10.1016/j.jtho.2019.03.030.CrossRefPubMed

61.

Henderson DW, Rödelsperger K, Woitowitz HJ, Leigh J. After Helsinki: a multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997–2004. Pathology. 2004;36(6):517–50. https://doi.org/10.1080/00313020400010955.CrossRefPubMed

62.

Ngamwong Y, Tangamornsuksan W, Lohitnavy O, et al. Additive synergism between asbestos and smoking in lung cancer risk: a systematic review and meta-analysis. PLoS ONE. 2015;10(8):135798. https://doi.org/10.1371/JOURNAL.PONE.0135798.CrossRef

63.

Uguen M, Dewitte JD, Marcorelles P, et al. Asbestos-related lung cancers: a retrospective clinical and pathological study. Mol Clin Oncol. 2017;7(1):135–9. https://doi.org/10.3892/MCO.2017.1277.CrossRefPubMedPubMedCentral

64.

Dodson RF, O’Sullivan MF, Huang J, Holiday DB, Hammar SP. Asbestos in extrapulmonary sites: omentum and mesentery. Chest. 2000;117(2):486–93. https://doi.org/10.1378/CHEST.117.2.486.CrossRefPubMed

65.

Mukherjee S, De Klerk N, Palmer LJ, Olsen NJ, Pang SC, Musk AW. Chest pain in asbestos-exposed individuals with benign pleural and parenchymal disease. Am J Respir Crit Care Med. 2000;162(5):1807–11. https://doi.org/10.1164/AJRCCM.162.5.9912012.CrossRefPubMed

66.

Copley SJ, Wells AU, Rubens MB, et al. Functional consequences of pleural disease evaluated with chest radiography and CT. Radiology. 2001;220(1):237–43. https://doi.org/10.1148/RADIOLOGY.220.1.R01JL27237.CrossRefPubMed

67.

Cookson WOCM, De Klerk NH, Musk AW. Benign and malignant pleural effusions in former Wittenoom crocidolite millers and miners. Aust N Z J Med. 1985;15(6):731–7.PubMed

68.

Mattson SB. Monosymptomatic exudative pleurisy in persons exposed to asbestos dust. Scand J Respir Dis. 1975;56(5):263–72.PubMed

69.

Mintzer RA, Cugell DW. The association of asbestos-induced pleural disease and rounded atelectasis. Chest. 1982;81(4):457–60. https://doi.org/10.1378/CHEST.81.4.457.CrossRefPubMed

70.

Jeebun V, Stenton SC. The presentation and natural history of asbestos-induced diffuse pleural thickening. Occup Med (Lond). 2012;62(4):266–8. https://doi.org/10.1093/OCCMED/KQS028.CrossRefPubMed

71.

Norbet C, Joseph A, Rossi SS, Bhalla S, Gutierrez FR. Asbestos-related lung disease: a pictorial review. Curr Probl Diagn Radiol. 2015;44(4):371–82. https://doi.org/10.1067/j.cpradiol.2014.10.002.CrossRefPubMed

72.

Roach HD, Davies GJ, Attanoos R, Crane M, Adams H, Phillips S. Asbestos: when the dust settles - an imaging review of asbestos-related disease. Radiographics. 2002. https://doi.org/10.1148/radiographics.22.suppl_1.g02oc10s167.CrossRefPubMed

73.

McHugh K, Blaquiere RM. CT features of rounded atelectasis. Am J Roentgenol. 1989;153(2):257–60. https://doi.org/10.2214/ajr.153.2.257.CrossRef

74.

Markowitz SB, Levin SM, Miller A, Morabia A. Asbestos, asbestosis, smoking, and lung cancer: new findings from the north American insulator cohort. Am J Respir Crit Care Med. 2013;188(1):90–6. https://doi.org/10.1164/rccm.201302-0257OC.CrossRefPubMed

75.

Akira M, Yamamoto S, Yokoyama K, et al. Asbestosis: high-resolution CT-pathologic correlation. Radiology. 1990;176(2):389–94. https://doi.org/10.1148/RADIOLOGY.176.2.2367652.CrossRefPubMed

76.

Guidotti TL, Miller A, Christiani D, et al. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2012;170(6):691–715. https://doi.org/10.1164/RCCM.200310-1436ST.CrossRef

77.

Ollier M, Chamoux A, Naughton G, Pereira B, Dutheil F. Chest CT scan screening for lung cancer in asbestos occupational exposure: a systematic review and meta-analysis. Chest. 2014;145(6):1339–46. https://doi.org/10.1378/chest.13-2181.CrossRefPubMed

78.

Mensi C, Markowitz SB. Lung cancer screening in asbestos-exposed populations. Int J Environ Res Public Health. 2022;19(5):2688. https://doi.org/10.3390/IJERPH19052688.CrossRef

79.

Hoshi S, Tamai Y, Tamura A, et al. Silico-asbestosis that responded to steroid therapy. Intern Med. 2006;45(15):917–21. https://doi.org/10.2169/INTERNALMEDICINE.45.1656.CrossRefPubMed

80.

Addrizzo-Harris DJ, Harkin TJ, Tchou-Wong KM, et al. Mechanisms of colchicine effect in the treatment of asbestosis and idiopathic pulmonary fibrosis. Lung. 2002;180(2):61–72. https://doi.org/10.1007/S004080000083.CrossRefPubMed

81.

Afaq F, Abidi P, Rahman Q. N-acetyl L-cysteine attenuates oxidant-mediated toxicity induced by chrysotile fibers. Toxicol Lett. 2000;117(1–2):53–60. https://doi.org/10.1016/S0378-4274(00)00236-8.CrossRefPubMed

82.

Alfonso H, Franklin P, Ching S, et al. Effect of N-acetylcysteine supplementation on oxidative stress status and alveolar inflammation in people exposed to asbestos: a double-blind, randomized clinical trial. Respirology. 2015;20(7):1102–7. https://doi.org/10.1111/RESP.12592.CrossRefPubMed

83.

• Rytz F, Poellinger A, Berezowska S, Geiser T, Funke-Chambour M. Pirfenidone as a treatment for asbestos-related lung fibrosis? A retrospective case series. Eur Respir J. 2018;52(suppl 62):PA2993. https://doi.org/10.1183/13993003.CONGRESS-2018.PA2993. This study studies some benefit of a Pirfenidone as a possible therapy of asbestos-related disease.

84.

• Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;41(1):27–34. https://doi.org/10.1016/J.CTRV.2014.10.007. This paper highlights the novel therapy for the management of asbestos-related lung disease.

Title: Asbestos-Related Diseases and Its Impact on Health: An Updated Review Article
Authors: Wasey Ali Yadullahi Mir
Ayusha Poudel
Anurag Adhikari
Dhan Bahadur Shrestha
Yubraj Sedhai
Peter LaCamera
Andrew Moraco
Publication date: 28-10-2023
Publisher: Springer US
Keywords: Asbestos-Related Disease
Asbestosis
Mesothelioma
Lung Cancer
Pleural Effusion
Lung Cancer
Lung Cancer
Published in: Current Pulmonology Reports / Issue 4/2023
Electronic ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-023-00324-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Asbestos/© ALEXEY / stock.adobe.com, Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2023

Pleuroscopy: Update on Indications, Techniques, and Limitations

Making Mountains Out of Molehills: Scoring Hypopnea Based on 3 and 4% Desaturation of Oxyhemoglobin

Endobronchial ultrasound staging for lung cancer

Airway complications of lung transplantation

Genetic testing in interstitial lung disease

Bronchoscopy-related infection and the development of single-use technology

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage